Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
Submitted by
admin
on March 15, 2024 - 11:13am
Source:
Motley Fool
News Tags:
Pfizer
obesity
M&A
Viking Therapeutics
Headline:
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
snippet:
Pfizer's pipeline already includes two obesity drugs.
However, doubts about Pfizer's lead obesity program could make buying Viking a smart move.
The best bet is that Pfizer will wait for additional data before moving forward with any potential acquisition.
Do Not Allow Advertisers to Use My Personal information
